Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma

Hou, Shengzhong; Chen, Xing; Li, Mao; Huang, Xing; Liao, Haotian; Tian, Bole

doi:10.18632/aging.103501

Cited by 10 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CDCA5 is the main regulator of sister chromatid separation and aggregation and has an important regulatory role in cell division [25,26]. Many recent studies have shown that CDCA5 can be used as a negative prognostic marker for HCC and have demonstrated that its regulatory cell division mechanism plays an important role in the occurrence and development of HCC [27][28][29]. A recent study suggested that RHPN1-AS1 can promote CDCA5 expression by functioning as a competing endogenous RNA for miR-485.…”

Section: Discussionmentioning

confidence: 99%

Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma

Zhang

Lin

et al. 2021

Bioengineered

View full text Add to dashboard Cite

RNA-binding motif protein 25 (RBM25) is a poorly characterized RNA-binding protein that is involved in several biological processes and regulates the proliferation and metastasis of tumor cells. The regulatory role of RBM25 in hepatocellular carcinoma (HCC) is unknown. Here, RBM25 expression and outcomes in HCC patients were evaluated using The Cancer Genome Atlas database. RBM25 was overexpressed in HCC patients compared with the healthy group. The high expression of RBM25 in tumor tissues was significantly related to poor overall survival (P<0.001). Overexpression of RBM25 significantly contributed to poorer survival in male patients and N0 stage patients (P<0.001). Spearman analysis and weighted gene co-expression network analysis identified 694 RBM25-related genes. Protein-protein interaction network analysis revealed the Cluster with the highest score, which positively correlated with RBM25. CDCA5 and INCENP were identified as the core functional genes related to RBM25. The overexpression of CDCA5 and INCENP in HCC patients was examined using the Human Protein Atlas database. The findings collectively indicated that RBM25 may interact with CDCA5 and INCENP to regulate HCC. Our detailed characterization of RBM25 protein interactions and related core functional genes provides a basis for further studies aimed at identifying molecular regulatory pathways or splicing events.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma

Zhang

Lin

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…In hepatocellular carcinoma, knockdown of CDCA5 by lentivirusmediated shRNA resulted in cell cycle arrest at the G2/M phase and cell apoptosis [19]. Moreover, higher expression of CDCA5 in hepatocellular carcinoma was associated with increased tumor size, microvascular in ltration, as well as poor prognosis of OS and DFS [20,21]. Likewise, CDCA5 knockdown could inhibit the growth of esophageal squamous cell carcinoma cells.…”

Section: Discussionmentioning

confidence: 99%

Identification of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis

Cao

Meng

Huang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Multiple myeloma is a hematologic disorder of abnormal plasma cell proliferation. Although there are some agents with different mechanisms in the clinic, the treatment of multiple myeloma is still challenging for the reason that its recurrence and progression are common. Therefore, it is critical to determine novel biomarkers to improve the prognosis of patients. Methods Firstly, raw data of GSE82307 was collected from the Gene Expression Omnibus database. Secondly, the top 50% of most variant genes were employed to construct a gene co-expression network in the R.WGCNA algorithm, and module significance and module membership were utilized to identify hub modules and hub genes respectively. The gene ontology enrichment and Kyoto encyclopedia of genes and genomes pathway analysis were carried out to assess biological characteristics. Then a protein-protein interaction network was conducted based on the STRING website and Cytoscape software. Next, differentially expressed genes were analyzed using the limma R package. Finally, survival analysis was performed by Kaplan–Meier plotter to evaluate prognosis. Results 10826 genes were used to construct a co-expression network. In this network, the blue module was identified as a hub module in which 68 genes were identified as hub genes. Furthermore, 46 differentially expressed genes were screened in samples of GSE82307. Integrating hub genes and differentially expressed genes, we determined 14 key genes. Finally, survival analysis revealed that ten genes CDCA5, CEP55, HJURP, CDC20, FOXM1, RRM2, TTK, CENPE, SKA1, NUF2 were related to the relapse and prognosis of multiple myeloma. Conclusion Our study suggested that CDCA5, CEP55, HJURP, CDC20, FOXM1, RRM2, TTK, CENPE, SKA1, NUF2 may be potential biomarkers for predicting the relapse and prognosis of multiple myeloma.

show abstract

“…CDCA5 can also promote cell proliferation and participate in apoptosis by regulating the function of cell cycle related proteins and transcription factors [10]. As reported, upregulated CDCA5 expression level was found in many types of cancers, including bladder cancer, lung cancer, liver cancer, colorectal cancer, indicating CDCA5 may participate in the development of these diseases [11][12][13][14]. However, the functional role of CDCA5 in ccRCC progression remains unclear.…”

Section: Introductionmentioning

confidence: 86%

CDCA5 is a potent therapeutic target of clear cell renal cell carcinoma

Wang

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adult, and patients with advanced ccRCC are facing limited treatment options. Cell division cycle associated 5 (CDCA5), a key regulator for segregating sister chromatids in cell cycle, has been increasingly reported for a potential therapeutic target in multiple human cancers. However, the functional roles of CDCA5 in ccRCC remain uncertain. Here we identified that CDCA5 expression was frequently upregulated in ccRCC tumors and significantly associated with poor prognosis of ccRCC patients. To investigate the role of CDCA5 in ccRCC progression, loss function cell models were established. Knockdown of CDCA5 remarkably suppressed ccRCC cell proliferation and migration ability, and also induced cell apoptosis in vitro. In addition, the significance of CDCA5 in ccRCC was further demonstrated in a mouse xenograft model. Silencing of CDCA5 drastically inhibited in vivo tumorigenicity of ccRCC cells. Mechanically, we identified CDCA5 may cooperate with EEF1A1 to promote the tumorigenic phenotype of ccRCC. Overall, our results revealed the significant functional role of CDCA5 in ccRCC progression, which may pave a way for the development of new treatment strategies for ccRCC treatment.

show abstract

Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma

Cited by 10 publications

References 59 publications

Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma

Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma

Identification of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis

CDCA5 is a potent therapeutic target of clear cell renal cell carcinoma

Contact Info

Product

Resources

About